NHS’s breakthrough leukaemia therapy set to transform lives in UK

Clinical trials found that 77% of patients went into remission after receiving obe-cel

Zydus receives FDA’s tentative approval for Empagliflozin and Linagliptin tablets

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating

EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma

The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival

Thermo Fisher opens two new centers in Hyderabad

The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies